@article{LUO2022, 
author = {Xiangchong LUO and Zhouqing WANG and Qiongyan LI and Guibing MAO and Le AN and Jiahong ZHU and E'hong TAO and Lifei SUN and Shengfei WANG and Gaofeng LI},
title = {Pharmacological Effects and Clinical Evaluation of PD-1 Inhibitor of Tislelizumab in the Treatment of Advanced Malignant Tumors},
year = {2022},
journal = {Medical Journal of Peking Union Medical College Hospital},
volume = {13},
number = {4},
pages = {679-686},
keywords = {malignant tumor, PD-1 inhibitor, tislelizumab, immunotherapy},
url = {https://www.sciopen.com/article/10.12290/xhyxzz.2021-0691},
doi = {10.12290/xhyxzz.2021-0691},
abstract = {In recent years, immunotherapy has made breakthroughs in the field of malignant tumors, and more and more novel immune checkpoint inhibitors have been developed, revolutionizing the first-line, second-line and post-line treatment options for malignant tumors. Tislelizumab is a domestically developed inhibitor of programmed death-1 (PD-1). The drug has shown good antitumor potential and safety in classical Hodgkin's lymphoma, uroepithelial carcinoma, non-small cell lung cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma and gastric cancer/gastroesophageal junction carcinoma. In this review, the structure and mechanism of action, pharmacodynamics and pharmacokinetics, clinical research and adverse reactions of tislelizumab are reviewed to provide reference for clinical application.}
}